<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01100645</url>
  </required_header>
  <id_info>
    <org_study_id>VCPEMS0210</org_study_id>
    <secondary_id>Version 2</secondary_id>
    <nct_id>NCT01100645</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the Herbal Medicine Sominex ® (Passiflora Incarnata L., Valeriana Officinalis L. and Crataegus Oxyacantha L.), Manufactured by the Laboratory EMS S / A in Patients With Psychophysiological Insomnia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azidus Brasil</source>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the clinical efficacy of the drug Sominex&#xD;
      (Valeriana officinalis L., 40 mg, 30 mg Crataegus oxyacantha L. and Passiflora incarnata L.&#xD;
      50 mg) manufactured by the Laboratory EMS S / A, compared to placebo in improving sleep&#xD;
      efficiency, based on the response of the sleep quality questionnaire (MSQ) and&#xD;
      polysomnographic parameters described below:&#xD;
&#xD;
        -  Latency to onset of sleep;&#xD;
&#xD;
        -  Total time of sleep;&#xD;
&#xD;
        -  Rapid eye movement (REM) sleep latency;&#xD;
&#xD;
        -  Duration of REM sleep&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Verify the effectiveness of the drug Sominex compared to placebo based on the improvement of&#xD;
      the following parameters measured by the following validated scales:&#xD;
&#xD;
        -  Anxiety;&#xD;
&#xD;
        -  Daytime sleepiness; Will also be assessed secondary to drug safety testing for the&#xD;
           occurrence, type, frequency and intensity of adverse events during treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">February 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in sleep efficiency</measure>
    <time_frame>28 days of treatment.</time_frame>
    <description>Quality of Sleep Questionnaire and the polysomnographic parameters:&#xD;
Latency to onset of sleep;&#xD;
Total time of sleep;&#xD;
REM sleep latency;&#xD;
Duration of REM sleep;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of the values obtained by the answers of the questionnaires obtained during the treatment</measure>
    <time_frame>28 days of treatment.</time_frame>
    <description>Scale Hamilton Anxiety (HAM-A); Daytime Sleepiness Scale Epworth; Journal of Sleep</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sominex ® (Passiflora incarnata L. 50 mg, Valeriana officinalis L. 40 mg and Crataegus oxyacantha L. 30 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Excipient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sominex</intervention_name>
    <description>Passiflora incarnata L.50 mg Valeriana officinalis L.40 mg Crataegus oxyacantha L.30 mg</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Excipient</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who agree and sign the informed consent form (ICF);&#xD;
&#xD;
          2. Adult patients, aged ≥ 18 years and ≤ 65 years, male or female;&#xD;
&#xD;
          3. Patients who agree to perform all study procedures;&#xD;
&#xD;
          4. Patients diagnosed with psychophysiological insomnia;&#xD;
&#xD;
          5. Patients who present in the application of sleep questionnaire result ≥ 25 and ≤ 30&#xD;
             points;&#xD;
&#xD;
          6. Patients presenting in polysomnography change in any of the polysomnographic&#xD;
             parameters than the normal range.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Having participated in any experimental study or have ingested any drug trial within&#xD;
             12 months prior to the start of the study;&#xD;
&#xD;
          2. Be in use or have used other medications that interfere with the regular response of&#xD;
             the drug at least 04 weeks prior to the start of the study, as benzodiazeínicos,&#xD;
             antidepressants with sedative, sedatives, antihistamines and other herbal medicines;&#xD;
&#xD;
          3. Being in treating or have been treated with alternative methods that interfere with&#xD;
             the drug response to at least 04 weeks prior to the start of the study, such as&#xD;
             behavioral therapies and relaxation techniques, such as yoga, massage, etc.;&#xD;
&#xD;
          4. Be patient with sensitivity to an association of herbal medicines;&#xD;
&#xD;
          5. Present history of alcohol abuse, drugs or medicines;&#xD;
&#xD;
          6. Pregnant or nursing women;&#xD;
&#xD;
          7. Owning a history of liver disease or renal impairment and / or thyroid dysfunction;&#xD;
&#xD;
          8. Patients with a history of restless sleep: nocturnal myoclonus or restless legs&#xD;
             syndrome;&#xD;
&#xD;
          9. Patients with a history of snoring or bruxism exaggerated;&#xD;
&#xD;
         10. Diseases that affect sleep, causing pain or immobilization of the patient in bed;&#xD;
&#xD;
         11. Patients who have extensive work or working in night shifts totally or partially&#xD;
             nocturnal;&#xD;
&#xD;
         12. Patients in whom polysomnography demonstrating non-characteristic changes in sleep&#xD;
             disturbances of psychophysiological origin as narcolepsy, hipopinéia syndrome, upper&#xD;
             airway hypersensitivity syndrome of periodic limb movements, sleepwalking, among&#xD;
             others;&#xD;
&#xD;
         13. Physical or psychological disorders that might interfere with the analysis of data&#xD;
             such as neurosis, depression, muscle atrophy, and / or staying the medical criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LAL Clinica Pesquisa e Desenvolvimento Ltda</name>
      <address>
        <city>Valinhos</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandre Frederico</last_name>
      <phone>+55 19 3871-6399</phone>
      <email>alexandre@lalclinica.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>April 7, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <last_update_submitted>October 26, 2010</last_update_submitted>
  <last_update_submitted_qc>October 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Alexandre Frederico</name_title>
    <organization>LAL Clínica Pesquisa e Desenvolvimento Ltda.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

